The global demand for Vedolizumab Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028. Regarding volume, the market was calculated XX Kilo Tons in 2021 and forecast to touch XX Kilo Tons by 2028 with a CAGR of XX% during 2022-2028.
Vedolizumab is a monoclonal antibody used to treat bowel disorders, including ulcerative colitis (UC) and Crohn's disease (CD). It functions by blocking the actions of a specific natural substance in the body which helps decrease swelling and inflammation in the gut. Thus, it helps lessens symptoms and may slow or stop the damage from these bowel disorders. Vedolizumab is given by injection into a vein. It is sold under the brand name Entyvio. Unfortunately, Vedolizumab is more often to cause side effects including runny nose, sore throat, headache, joint pain, nausea, and fever.
Market Dynamics
The burden of inflammatory bowel disease (IBD) is rising globally, boosting the market growth. However, the incidence is growing with variation in trends and levels in different countries and regions. The prevalence of IBD is highest in developed countries and the lowest in developing areas. Globally, the incidence of inflammatory bowel disease is around 0.5-24.5 cases per 100,000 person-annually for ulcerative colitis and 0.1-16 cases per 100,000 person-annually for Crohn's disease, positively reflecting on sales of vedolizumab drug. Vedolizumab is the understudy for the treatment of HIV infection. Favorable results from clinical trials are estimated to create new market opportunities. However, the vedolizumab market is estimated to experience significant hindrance due to its side effects which also brain infection that can lead to disability or death.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of vedolizumab. The growth and trends of Vedolizumab Industry provide a holistic approach to this study.
Market Segmentation
This section of the vedolizumab market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Application
- Ulcerative Colitis
- Crohn's Disease
By End Use
- Hospitals & Clinics
- Academic & Research
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Vedolizumab market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Vedolizumab Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the vedolizumab market include Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.